Advertisement

Topics

iVeena Delivery Systems Completes Phase 1/2a Pilot Clinical Study of IVMED-10 for Post-Cataract Inflammation

10:00 EST 8 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
iVeena Delivery Systems (iVeena), a biopharmaceutical company that develops innovative ophthalmology products, today announced the successful completion of a pilot clinical trial for its lead product IVMED-10, a bioerodib...

Other Sources for this Article

iVeena Delivery Systems, Inc.
Michael Burr, MS, MBA, 801-550-5863
Vice President of Product Development
mburr@iveenamed.com

NEXT ARTICLE

More From BioPortfolio on "iVeena Delivery Systems Completes Phase 1/2a Pilot Clinical Study of IVMED-10 for Post-Cataract Inflammation"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Pain
Pain is defined by the International Association for the Study of Pain as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage”. Some illnesses can be excruci...